Additionally, the therapeutic efficacy of systemically administered oAd/APP was markedly lower than those achieved via intratumoral optimization, suggesting that further optimization in tumor-targeted delivery efficiency of the APP will be necessary to exert sufficient antitumor effect in a complex clinical tumor microenvironment. This evidence concerns the gene APP and neoplasm.